IL6R and rheumatoid arthritis: In addition, AIFA has authorized a study, due to be coordinated by the Pascale Institute of Naples, to evaluate the efficacy of tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R), mainly administered for the treatment of rheumatoid arthritis [14].